Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00610493 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab and Temsirolimus in Patients With Advanced Malignancy
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 193
- Enrollment target
NCT00610493: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00610493 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 193 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00610493, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 193 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of Avastin (bevacizumab) and Torisel (temsirolimus) that can be given, in combination, to patients with advanced cancer that has spread or is unable to be surgically removed. The safety of this drug combination will also be studied.
Interventions
- DRUG Bevacizumab
- PROCEDURE Biopsy
- DRUG Temsirolimus
- PROCEDURE Additional Blood Drawn
- PROCEDURE DCE-MRI Scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2008-01-25 |
| Est. Completion | 2017-11-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00610493
The ClinicalTrials.gov registry entry for NCT00610493 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT00610493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00610493 about?
NCT00610493 is a clinical study titled "Bevacizumab and Temsirolimus in Patients With Advanced Malignancy". The goal of this clinical research study is to find the highest tolerable dose of Avastin (bevacizumab) and Torisel (temsirolimus) that can be given, in combination, to patients with advanced cancer that has spread or is unable to be surgically removed. The safety of this drug combination will also ...
What is the current status of trial NCT00610493?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 193 participants. The study started on 2008-01-25. Estimated completion is 2017-11-28.
What interventions are being tested in trial NCT00610493?
The interventions under investigation include: Bevacizumab (DRUG), Biopsy (PROCEDURE), Temsirolimus (DRUG), Additional Blood Drawn (PROCEDURE), DCE-MRI Scan (PROCEDURE).
Who is sponsoring clinical trial NCT00610493?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.